GeneDx (NASDAQ:WGS) Stock Rating Upgraded by Zacks Research

GeneDx logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research upgraded GeneDx from “hold” to “strong buy.” Analysts overall have a “Moderate Buy” consensus and an average price target of $90.14.
  • GeneDx reported quarterly EPS of $0.28, beating the $0.07 consensus estimate, while revenue of $123.1 million slightly exceeded expectations.
  • The stock opened at $47.29; it has traded between $32.21 and $170.87 over the past year.
  • MarketBeat previews the top five stocks to own by December 1st.

GeneDx (NASDAQ:WGS - Get Free Report) was upgraded by Zacks Research from a "hold" rating to a "strong-buy" rating in a report released on Monday, Zacks reports.

A number of other equities analysts also recently issued reports on WGS. Canaccord Genuity Group increased their price target on shares of GeneDx from $75.00 to $90.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. BTIG Research reaffirmed a "buy" rating and set a $85.00 price objective (down from $90.00) on shares of GeneDx in a research report on Tuesday, November 10th. Weiss Ratings reiterated a "sell (d)" rating on shares of GeneDx in a report on Monday, November 2nd. Wall Street Zen upgraded GeneDx from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Guggenheim increased their target price on GeneDx from $74.00 to $83.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $90.14.

Read Our Latest Stock Analysis on WGS

GeneDx Stock Performance

NASDAQ:WGS opened at $47.29 on Monday. The company has a quick ratio of 3.85, a current ratio of 4.16 and a debt-to-equity ratio of 0.60. The firm's fifty day simple moving average is $72.36 and its 200 day simple moving average is $69.72. The stock has a market cap of $1.42 billion, a P/E ratio of -12.51 and a beta of 2.00. GeneDx has a twelve month low of $32.21 and a twelve month high of $170.87.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.07 by $0.21. GeneDx had a negative net margin of 24.10% and a positive return on equity of 1.98%. The business had revenue of $123.10 million during the quarter, compared to analyst estimates of $122.93 million. During the same period in the prior year, the business earned ($0.27) EPS. As a group, research analysts predict that GeneDx will post -0.41 EPS for the current year.

Insider Transactions at GeneDx

In related news, CEO Katherine Stueland sold 10,501 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $1,025,002.61. Following the completion of the transaction, the chief executive officer directly owned 115,476 shares in the company, valued at $11,271,612.36. This trade represents a 8.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $363,890.08. Following the transaction, the chief financial officer directly owned 44,945 shares of the company's stock, valued at approximately $4,387,081.45. This trade represents a 7.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 19,206 shares of company stock worth $1,808,056 over the last ninety days. Insiders own 25.17% of the company's stock.

Hedge Funds Weigh In On GeneDx

Large investors have recently made changes to their positions in the business. William Blair Investment Management LLC increased its holdings in shares of GeneDx by 11.4% during the third quarter. William Blair Investment Management LLC now owns 1,560,247 shares of the company's stock valued at $112,806,000 after acquiring an additional 159,594 shares in the last quarter. First Light Asset Management LLC raised its position in shares of GeneDx by 222.7% in the 2nd quarter. First Light Asset Management LLC now owns 783,923 shares of the company's stock worth $53,816,000 after purchasing an additional 540,996 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of GeneDx by 108.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 632,413 shares of the company's stock worth $45,723,000 after purchasing an additional 328,980 shares during the last quarter. Wellington Management Group LLP boosted its stake in GeneDx by 2.0% in the 2nd quarter. Wellington Management Group LLP now owns 347,927 shares of the company's stock worth $23,885,000 after purchasing an additional 6,922 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in GeneDx by 38.6% in the 1st quarter. Bank of New York Mellon Corp now owns 315,508 shares of the company's stock worth $20,262,000 after purchasing an additional 87,922 shares in the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About GeneDx

(Get Free Report)

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company's testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.

Featured Articles

Analyst Recommendations for GeneDx (NASDAQ:WGS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GeneDx Right Now?

Before you consider GeneDx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.

While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines